RTW Investments LP Buys 111,123 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

RTW Investments LP raised its position in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 2.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,591,700 shares of the biopharmaceutical company's stock after acquiring an additional 111,123 shares during the quarter. RTW Investments LP owned approximately 9.14% of Sage Therapeutics worth $40,372,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. lifted its stake in Sage Therapeutics by 43.6% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 37,572 shares of the biopharmaceutical company's stock valued at $408,000 after purchasing an additional 11,409 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Sage Therapeutics in the second quarter valued at approximately $177,000. Assenagon Asset Management S.A. boosted its stake in shares of Sage Therapeutics by 6.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 167,225 shares of the biopharmaceutical company's stock worth $1,816,000 after acquiring an additional 10,632 shares during the period. Values First Advisors Inc. increased its holdings in shares of Sage Therapeutics by 62.0% during the 2nd quarter. Values First Advisors Inc. now owns 28,962 shares of the biopharmaceutical company's stock worth $315,000 after acquiring an additional 11,086 shares during the last quarter. Finally, Easterly Investment Partners LLC raised its stake in Sage Therapeutics by 24.6% in the 2nd quarter. Easterly Investment Partners LLC now owns 136,602 shares of the biopharmaceutical company's stock valued at $1,483,000 after acquiring an additional 27,000 shares during the period. Institutional investors and hedge funds own 99.22% of the company's stock.

Sage Therapeutics Stock Performance

Shares of Sage Therapeutics stock traded down $0.01 on Thursday, reaching $5.60. 846,410 shares of the stock were exchanged, compared to its average volume of 962,627. The firm has a market cap of $342.55 million, a PE ratio of -1.00 and a beta of 0.87. The firm's 50 day moving average is $6.37 and its 200-day moving average is $8.64. Sage Therapeutics, Inc. has a one year low of $4.62 and a one year high of $28.26.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing the consensus estimate of ($1.52) by ($0.01). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The business had revenue of $11.87 million for the quarter, compared to the consensus estimate of $10.80 million. During the same quarter in the previous year, the company earned ($2.81) earnings per share. The firm's revenue for the quarter was up 337.1% on a year-over-year basis. On average, equities research analysts expect that Sage Therapeutics, Inc. will post -6.53 EPS for the current fiscal year.

Analyst Ratings Changes

SAGE has been the subject of a number of research analyst reports. Wedbush reduced their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a "neutral" rating for the company in a research report on Wednesday, October 9th. Truist Financial reduced their target price on shares of Sage Therapeutics from $13.00 to $8.00 and set a "hold" rating for the company in a report on Wednesday, October 30th. StockNews.com cut shares of Sage Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, October 31st. Bank of America reduced their price objective on Sage Therapeutics from $11.00 to $6.00 and set an "underperform" rating for the company in a report on Wednesday, October 9th. Finally, Raymond James reissued a "market perform" rating on shares of Sage Therapeutics in a report on Thursday, October 10th. Three equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $12.83.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.